AHCO 8-K/A filed 2026 · insiderdelta

Item 5.02. Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 5, 2026, AdaptHealth Corp. (the “Company”)
filed a Current Report on Form 8-K (the “Original Filing”) reporting, among other things, the appointment of Daniel McFadden
as Chief Operating Officer of the Company, effective as of May 4, 2026 (the “Appointment Date”). The Original Filing
inadvertently reported the Date of Report (Date of earliest event reported) on the cover page as May 5, 2026, when it should have been
reported as May 4, 2026. The Company is filing this Amendment No. 1 on Form 8-K/A (this “Amendment No. 1”) to (i) correct
the incorrect Date of Report on the Original Filing and (ii) provide additional information regarding material changes to Mr. McFadden’s
compensation that had not been determined at the time of the Original Filing. This Amendment No. 1 supplements the Original Filing and
should be read in conjunction with the Original Filing.

On May 27, 2026, in connection with Mr. McFadden’s
promotion to Chief Operating Officer, the Compensation Committee of the Company’s Board of Directors (the “Committee”)
approved an increase to Mr. McFadden’s annual base salary from $410,000 to $550,000, with retroactive effect to the Appointment
Date. Mr. McFadden will continue to be eligible to receive an annual incentive bonus with a target amount equal to 100% of his increased
base salary. For the Company’s 2026 fiscal year, such target bonus amount and any actual bonus payable will be pro-rated based on
the actual base salary paid to Mr. McFadden in 2026. The Committee also approved a one-time grant of restricted stock units covering
a number of shares of the Company’s common stock with a value of $464,110 (determined in a manner consistent with the Company’s
historic practices) pursuant to the Company’s Second Amended and Restated 2019 Stock Incentive Plan, 50% of which will vest in equal
installments annually over three years and 50% of which will be eligible to vest between 0% and 200% based on the Company’s total
shareholder return (“TSR”) relative to the TSRs of the Company’s peer companies over a three-year performance period
beginning on February 1, 2026, subject to Mr. McFadden’s continued employment with the Company.

Except as expressly stated herein, this Amendment
No. 1 does not amend or update any other information contained in the Original Filing, which remains unchanged.

AHCO Adapthealth Corp. - 8-K/A

Item 5.02 - Departure/Election of Directors or Certain Officers

Item 9.01 - Financial Statements and Exhibits